Although IL-17A concentration was higher in treatment naïve patients (mean ± SD: 25.94 ± 41.18 pg/ml; median: 13.64 pg/ml; range: 0.65–200.54 pg/ml) compared to those on any IBD treatment (mean ± SD: 14.14 ± 13.84 pg/ml; median: 8.86 pg/ml; range: 1.09–58.56 pg/ml), the difference was not statistically significant (p = 0.23). Here, IL17A is linked to inflammatory bowel disease.